Category: Lilly
-
Where Will Eli Lilly Be in 5 Years?
•
It is difficult to argue with the types of results Eli Lily (NYSE: LLY) It has been produced over the past five years. The company was one of the best drug giants, leaving its shares the broader market in dust. Some may argue that it is too late for Eli…
-
Roche falls while Novo, Lilly gain on weight-loss drug report (OTCQX:RHHBY)
•
HJBC Roche (OTCQX: RHHBY) shares fell 5% on Wednesday while shares of rivals Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) gained ground after Reuters reported that positive data from Roche (OTCQX:RHHBY) in July The obesity drug candidate CT-996 was based on just six study participants. In July, Roche said a…
-
Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound By Investing.com
•
Shares of Hims & Hers Health fell more than 6% Tuesday morning in response to Eli Lilly’s (NYSE:) latest announcement. Lilly announced that it has launched single-dose vials of its obesity drug, Zebound, at a 50% discount to other incretins, a move that comes amid growing competition in the obesity…
-
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters
•
(Reuters) – Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug developer Morphek surged 76% to $56.15 premarket after Lilly’s offer…
-
UK Planning Laws Hinder Investment, Warns Eli Lilly CEO
•
The head of the world’s largest drugs company has criticised the UK’s planning system, claiming it stifles investment. Dave Ricks, chief executive of Eli Lilly, a maker of obesity drugs, said current planning processes in the UK were a major barrier to building factories quickly, unlike in the US and…
-
Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
•
Al-Naylam Pharmaceuticals CompanyNasdaq: ALLNEY) The best-performing large-cap company ($30+ billion) was in the pharmaceutical or biotechnology space in the second quarter, Yield ~58.5% In the period. The biotech company’s strong performance was helped significantly in late June when it announced strong pivotal trial results for vutrisiran, a treatment for ATTR…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued? (NYSE:LLY)
•
jetcityimage Eli Lilly shares (New York Stock Exchange: LLY) and Novo Nordisk (NVO) in recent months, driven by growing demand for the companies’ weight-loss/diabetes drugs tirzepatide, also known as Mounjaro and Zepbound, and semaglutide, known as Ozempic and Wegovy. more Over the past 12 months, Lilly shares are up 76%…
-
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
•
Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly’s stock more than quadrupling and Novo’s stock more than tripling over the past three years. while, Pfizer’s (NYSE: PFE) Fortunes…
-
Denmark’s Novo Nordisk expects 27% sales surge this year but faces price pressure for weight loss drug Wegovy amid Eli Lilly competition
•
Novo Nordisk A/S raised its earnings forecast as the drugmaker now ships five times more introductory doses of the weight-loss drug Wegovy in the US than at the end of last year. More than 25,000 patients are now starting treatment each week in the United States, CEO Lars Frørgaard Jørgensen…